Pieris

Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy

...WEIHENSTEPHAN, Germany, November 8 /PRNewswire/ -- pieris AG, a biopharmaceutical company developing Antical...a Stern as Chief Operating Officer to the Company. pieris has also announced the promotion with immediate ef... Officer. The appointment of Dr Angelika Stern at pieris coincides with continued progress of the Company's...

Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology

...WEIHENSTEPHAN, Germany, October 30 /PRNewswire/ -- pieris AG (Munich, Germany) and Pepscan Therapeutics (Lel... and their development as therapeutic candidates. pieris has pioneered Anticalins(R) as next generation tar...h therapeutic potential". Notes to editors About pieris AG ...

Pieris in Medical Technology

Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050

FREISING-WEIHENSTEPHAN and JENA, Germany, July 17 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, and Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, announced yesterday a s...

Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist

...WEIHENSTEPHAN, Germany, February 3 /PRNewswire/ -- pieris AG, a biopharmaceutical company developing Antical...he mode of action of PRS-050 in vitro and in vivo, pieris has now validated the efficacy of the Anticalin(R)... Progress in the PRS-050 program demonstrates that pieris has fulfilled critical speed and capacity goals in...

Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin in Preclinical Studies

..., USA. "This example highlights perfectly how pieris is able to adapt pharmacokinetic properties of Ant...rable product profile." Notes to Editors About pieris AG pieris is a biopharmaceutical company engaged in the disc...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

...Director of Science and Preclinical Development of pieris said: "As Pieris continues to validate the therape...nants on two defined clinically validated targets, pieris has constructed Duocalins(R) as monomeric, bivalen...y of the Anticalin(R) scaffold has already allowed pieris to develop therapeutic and diagnostic product cand...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

...tion via the lungs. PRS-060 has been selected by pieris as being specific for a target implicated in a mec...covery Technology Conference in Boston, MA, USA. pieris is now actively seeking development partners for t...in(R) and Duocalin(R) are registered trademarks of pieris AG. For further information, please contact:...

Pieris in Biological News

Secret of worm's poison pill box protein could produce new natural insecticide

... of a caterpillar’s gut called "Brush Border Membrane Vesicles" (BBMV). The XptA1 protein seemed to specifically target the BBMV of caterpillars pieris Brassicae ?(The cabbage white butterfly caterpillar which are pests for many growers). The hollow box structure appears to be a key element of the pr...

Pieris in Biological Technology

Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round

...G-WEIHENSTEPHAN, Germany, March 27 /PRNewswire/ -- pieris AG, a bio-pharmaceutical company developing Antica... marks a significant milestone in the evolution of pieris as a product-focused biopharmaceutical company. Ha...nowned investors such as OrbiMed and Novo Nordisk, pieris is now in the position to deliver on its strategy ...

Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics

...EIHENSTEPHAN, Germany, September 5 /PRNewswire/ -- pieris AG, a bio-pharmaceutical company developing Antica...n ophthalmologic disease. The studies reported by pieris relate to PRS-055, an Anticalin(R) specific for VE...s-ag.com Anticalin(R) is registered trademark of pieris AG. For further information, please contact: ...